Citations to this article
Citation Information: J Clin Invest. 2022;132(6):e157990. https://doi.org/10.1172/JCI157990.
Abstract
BACKGROUND Immunization against SARS-CoV-2, the causative agent of COVID-19, occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last.METHODS We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to 1 year after infection and following mRNA vaccination in naive individuals and individuals recovered from COVID-19 infection.RESULTS We found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly, especially in naive individuals. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naive individuals, whereas it was ineffective in previously SARS-CoV-2–infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to 1 year following natural infection in a cohort of unvaccinated individuals.CONCLUSION Short-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. In naive individuals, a booster dose restored optimal anti-spike immunity, whereas the needs for vaccinated individuals who have recovered from COVID-19 have yet to be defined.FUNDING This study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018–2022), the University of Florence (project RICTD2122), the Italian Ministry of Health (COVID-2020-12371849), and the region of Tuscany (TagSARS CoV 2).
Authors
Alessio Mazzoni, Anna Vanni, Michele Spinicci, Giulia Lamacchia, Seble Tekle Kiros, Arianna Rocca, Manuela Capone, Nicoletta Di Lauria, Lorenzo Salvati, Alberto Carnasciali, Elisabetta Mantengoli, Parham Farahvachi, Lorenzo Zammarchi, Filippo Lagi, Maria Grazia Colao, Francesco Liotta, Lorenzo Cosmi, Laura Maggi, Alessandro Bartoloni, Gian Maria Rossolini, Francesco Annunziato
Citations to this article (24)
| Title and authors | Publication | Year |
|---|---|---|
|
Longitudinal analysis of nursing home residents’ T cell responses after SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2 infection history
Carson L. Smith, Elise Didion, Htin Aung, Banumathi Tamilselvan, Taissa Bej, Oladayo Oyebanji, Carey Shive, Brigid Wilson, Mark Cameron, Cheryl Cameron, Stefan Gravenstein, David Canaday |
The Journal of Infectious Diseases | 2024 |
|
Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Vanetti C, Stracuzzi M, Crivellaro E, Ciciliano F, Garziano M, Fenizia C, Biasin M, Rubinacci V, Amendola A, Tanzi E, Zuccotti GV, Clerici M, Giacomet V, Trabattoni D |
Frontiers in immunology | 2024 |
|
Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2
Safont G, Villar-Hernández R, Smalchuk D, Stojanovic Z, Marín A, Lacoma A, Pérez-Cano C, López-Martínez A, Molina-Moya B, Solis AJ, Arméstar F, Matllo J, Díaz-Fernández S, Romero I, Casas I, Strecker K, Preyer R, Rosell A, Latorre I, Domínguez J |
Scientific Reports | 2024 |
|
Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants.
Samanta S, Banerjee J, Das A, Das S, Ahmed R, Das S, Pal A, Ali KM, Mukhopadhyay R, Giri B, Dash SK |
Current Microbiology | 2024 |
|
Prolonged SARS-CoV-2 T Cell Responses in a Vaccinated COVID-19-Naive Population
Pitiriga VC, Papamentzelopoulou M, Konstantinakou KE, Vasileiou IV, Konstantinidis AD, Spyrou NI, Tsakris A |
Human vaccines | 2024 |
|
Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.
Alessandra R, Sara C, Claudia P, Natasha G, Federica C, Chiara B, Tobia F, Stefano T, Eleonora R, Andrea M, Martin MN, Caterina UF, Nigel T, Stefania DSM, Lucia L, Chiara P |
Journal of Translational Medicine | 2024 |
|
Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report
Hirano H, Asada H |
Journal of Medical Case Reports | 2024 |
|
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Maaske J, Sproule S, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Robb ML, Rolle CP, Sha BE, Tong T, Ahani B, Aksyuk AA, Bansal H, Egan T, Jepson B, Padilla M, Patel N, Shoemaker K, Stanley AM, Swanson PA 2nd, Wilkins D, Villafana T, Green JA, Kelly EJ |
Frontiers in immunology | 2023 |
|
SARS-CoV2 mRNA-vaccination-induced Immunological Memory in Human Non-Lymphoid and Lymphoid Tissues
Vanessa Pross, Arne Sattler, Sören Lukassen, Laura Tóth, Linda Thole, Janine Siegle, Carolin Stahl, An He, Georg Damm, Daniel Seehofer, Christina Götz, Christian Bayerl, Pia Jäger, Alexander Macke, Stephan Eggeling, Bernadette Kirzinger, Thomas Mayr, Hermann Herbst, Katharina Beyer, Dominik Laue, Jan Krönke, Jan Braune, Friederike Rosseck, Frank Friedersdorff, Mandy Hubatsch, Sarah Weinberger, Nils Lachmann, Veit Hofmann, Eva Schrezenmeier, Carolin Ludwig, Hubert Schrezenmeier, Katharina Jechow, Christian Conrad, Katja Kotsch |
Journal of Clinical Investigation | 2023 |
|
The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
Hein S, Sabino C, Benz NI, Görgülü E, Maier TJ, Oberle D, Hildt E |
Scientific Reports | 2023 |
|
SARS-CoV-2 Rapid Antigen Test Based on a New Anti-Nucleocapsid Protein Monoclonal Antibody: Development and Real-Time Validation.
Coelho FF, da Silva MA, Lopes TB, Polatto JM, de Castro NS, Andrade LAF, Lourenço KL, Sato HI, de Carvalho AF, Coelho HP, Bagno FF, Luz D, Viala VL, Cattony PQ, Melo BS, Moro AM, Quintilio W, Barbosa AP, Bomfim CG, Soares CP, Guzzo CR, Fonseca FG, Durigon EL, Gazzinelli RT, Ribeiro Teixeira SM, Piazza RMF, Fernandes AP |
Microorganisms | 2023 |
|
Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients.
Vanni A, Salvati L, Mazzoni A, Lamacchia G, Capone M, Francalanci S, Kiros ST, Cosmi L, Puccini B, Ciceri M, Sordi B, Rossolini GM, Annunziato F, Maggi L, Liotta F |
Frontiers in immunology | 2023 |
|
Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization
Giulia Lamacchia, Alessio Mazzoni, Michele Spinicci, Anna Vanni, Lorenzo Salvati, Benedetta Peruzzi, Sara Bencini, Manuela Capone, Alberto Carnasciali, Parham Farahvachi, Arianna Rocca, Seble Kiros, Lucia Graziani, Lorenzo Zammarchi, Jessica Mencarini, Maria Colao, Roberto Caporale, Francesco Liotta, Lorenzo Cosmi, Gian Rossolini, Alessandro Bartoloni, Laura Maggi, Francesco Annunziato |
2022 | |
|
Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
R Busà, M Sorrentino, G Russelli, G Amico, V Miceli, M Miele, M Bella, F Timoneri, A Gallo, G Zito, D Carlo, P Conaldi, M Bulati |
Frontiers in immunology | 2022 |
|
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga E, Lynton-Pons E, Domingo P |
Frontiers in immunology | 2022 |
|
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
Benucci M, Damiani A, Gobbi FL, Lari B, Grossi V, Infantino M, Manfredi M |
Immunologic research | 2022 |
|
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19
Zavaglio F, Cassaniti I, Sammartino JC, Tonello S, Sainaghi PP, Novelli V, Meloni F, Lilleri D, Baldanti F |
Microorganisms | 2022 |
|
Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study
Panico A, Lobreglio G, Bagordo F, Zizza A, De Donno A, Rosato C, Lazzari R, Chicone M, Indino F, Recchia V, Alifano P, Grassi T |
Human vaccines | 2022 |
|
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Decru B, Van Elslande J, Steels S, Van Pottelbergh G, Godderis L, Van Holm B, Bossuyt X, Van Weyenbergh J, Maes P, Vermeersch P |
Frontiers in immunology | 2022 |
|
Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
Fernández-Ciriza L, González Á, del Pozo JL, Fernández-Montero A, Carmona-Torre F, Carlos S, Sarasa MD, Reina G |
Scientific Reports | 2022 |
|
Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
Gobeil P, Pillet S, Boulay I, Charland N, Lorin A, Cheng MP, Vinh DC, Boutet P, Van Der Most R, Roman F, Ceregido MA, Landry N, D\u2019Aoust MA, Ward BJ |
Nature Communications | 2022 |
|
Current understanding of T cell immunity against SARS-CoV-2
Lu X, Yamasaki S |
Ensho Saisei | 2022 |
|
Fourth Dose of mRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH)
Lamacchia G, Salvati L, Kiros ST, Mazzoni A, Vanni A, Capone M, Carnasciali A, Farahvachi P, Lagi F, Di Lauria N, Rocca A, Colao MG, Liotta F, Cosmi L, Rossolini GM, Bartoloni A, Maggi L, Annunziato F |
Biomedicines | 2022 |
|
B-Cell Responses to Sars-Cov-2 mRNA Vaccines
Kardava L, Buckner CM, Moir S |
Pathogens and Immunity | 2022 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)